デフォルト表紙
市場調査レポート
商品コード
1507897

急性心不全（AHF）治療の世界市場

Acute Heart Failure (AHF) Therapeutics

出版日
ページ情報
英文 299 Pages
納期
即日から翌営業日
適宜更新あり
急性心不全（AHF）治療の世界市場
出版日: 2024年07月05日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 299 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

世界の急性心不全（AHF）治療の市場規模は、2030年までに29億米ドルに達する見込み

世界の急性心不全（AHF）治療の市場規模は、2023年に7億4,870万米ドルに達し、2023～2030年の分析期間中にCAGR 21.3%で成長し、2030年には29億米ドルに達すると予測されています。当レポートで分析したセグメントの1つである心臓配糖体は、CAGR 21.8%を記録し、分析期間終了時には7億6,240万米ドルに達すると予測されます。B遮断薬セグメントの成長率は、分析期間中CAGR 24.6%と推定されます。

米国の市場規模は2億40万米ドル、中国はCAGR 30.1%で成長する見込み

米国の急性心不全（AHF）治療の市場規模は、2023年に2億40万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8億4,120万米ドルの市場規模に達すると予測され、分析期間2023～2030年のCAGRは30.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に15.6%と17.8%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR約16.5%で成長すると予測されています。

急性心不全（AHF）治療：主要動向と促進要因

急性心不全（AHF）は、心不全症状の突然の発現や既存の心臓状態の悪化によって特徴づけられる重篤な状態であり、心臓が十分な血液を送り出すことができないために深刻な健康リスクをもたらします。全身的なうっ血と潜在的な臓器機能障害を伴うこの医療緊急事態は、患者の生存を確保し、生活の質を維持するために、即時かつ効果的な管理戦略を必要とします。AHFの病態生理は複雑で、さまざまな心臓の異常に起因する可能性があるため、その治療は複雑であり、de novo心不全と急性減圧性心不全という2つの主な病型に対する差別化されたアプローチの必要性を強調しています。前者は心臓病の既往歴のない患者において、根本的な心臓の問題を特定するための包括的な診断が必要であるのに対し、後者は既存の慢性疾患の急激な悪化に対処することに重点を置きます。

AHFの治療プロトコールは、症状を管理し、心臓の機能低下の根本原因に対処することに重点を置いています。初期戦略としては、AHFの一般的な合併症である体液過多を緩和するための非侵襲的換気と利尿剤の迅速投与が一般的です。これらと並行して、血圧が安定している患者では心臓の負担を軽減するために血管拡張薬などの治療的介入が行われ、一方、血行動態の安定を維持するために強心剤の投与は重症例にのみ行われます。さらに、影響を受けやすい患者では血栓塞栓症を予防するために抗凝固薬の使用が推奨されており、有効性と安全性の両方を考慮したバランスの取れたアプローチの重要性が強調されています。さらに、長期管理を最適化し、再入院の可能性を減らすためには、退院後の早期フォローアップが重要であり、これは初期治療段階を超えた患者ケアへの積極的なアプローチを反映しています。

AHF治療薬の状況は、診断における技術的進歩、遠隔患者モニタリングの採用拡大、心不全に関する患者の意識向上と教育など、いくつかの成長要因に牽引されて進化しています。心臓画像診断とバイオマーカー診断における技術革新は、AHFの検出とモニタリングの精度を高め、タイムリーで個別化された治療介入を促進します。さらに、ヘルスケアシステムにおける人工知能と機械学習の統合は、患者評価の精度を高め、治療プロトコルを最適化することで、AHF治療に革命をもたらしています。遺伝子治療や生物学的製剤など、新規医薬品の開発や治療方法の拡大は、利用可能な治療選択肢の幅を広げ、多様な患者集団やヘルスケアプロバイダーにアピールしています。さらに、規制状況や償還状況の変化は、しばしば高額ではあるもの、先進的な治療の採用を後押ししています。AHFは引き続き、病院での再入院や死亡の主な原因となっているため、これらの要因は総体的に、新たな治療戦略のダイナミックな進展と採用に寄与し、AHF管理の将来を形成しています。

調査対象企業の例（全93件）

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardiorentis AG
  • CVie Therapeutics Limited
  • Cytokinetics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • PhaseBio Pharmaceuticals, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他のアジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他の中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6845

Global Acute Heart Failure (AHF) Therapeutics Market to Reach US$2.9 Billion by 2030

The global market for Acute Heart Failure (AHF) Therapeutics estimated at US$748.7 Million in the year 2023, is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 21.3% over the analysis period 2023-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.8% CAGR and reach US$762.4 Million by the end of the analysis period. Growth in the B-Blockers segment is estimated at 24.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$200.4 Million While China is Forecast to Grow at 30.1% CAGR

The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$200.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$841.2 Million by the year 2030 trailing a CAGR of 30.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 17.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.5% CAGR.

ACUTE HEART FAILURE (AHF) THERAPEUTICS - KEY TRENDS AND DRIVERS

Acute heart failure (AHF) is a critical condition marked by the sudden onset of heart failure symptoms or the worsening of existing heart conditions, posing severe health risks due to the heart's inability to pump sufficient blood. This medical emergency, involving systemic congestion and potential organ dysfunction, requires immediate and effective management strategies to ensure patient survival and maintain quality of life. The complexity of AHF's pathophysiology, which can stem from a variety of cardiac abnormalities, complicates its treatment and highlights the necessity of differentiated approaches for its two main forms: de novo heart failure and acutely decompensated heart failure. While the former demands a comprehensive diagnosis to identify the underlying cardiac issue in patients with no prior history of heart disease, the latter focuses on managing the abrupt deterioration of an existing chronic condition.

Treatment protocols for AHF emphasize managing symptoms and addressing the root causes of the heart's reduced functionality. Initial strategies typically include non-invasive ventilation and rapid administration of diuretics to alleviate fluid overload, which is a common complication of AHF. Alongside these, other therapeutic interventions such as vasodilators are used to reduce cardiac load in patients with stable blood pressure, while inotropic support is reserved for severe cases to maintain hemodynamic stability. Additionally, the use of anticoagulants is recommended to prevent thromboembolic events in susceptible patients, underscoring the importance of a balanced approach that considers both efficacy and safety. Moreover, an early post-discharge follow-up is crucial for optimizing long-term management and reducing the chances of hospital readmission, reflecting a proactive approach to patient care that extends beyond the initial treatment phase.

The landscape of AHF therapeutics is evolving, driven by several growth factors including technological advancements in diagnostics, increased adoption of remote patient monitoring, and greater patient awareness and education about heart failure. Innovations in cardiac imaging and biomarker diagnostics enhance the precision of AHF detection and monitoring, facilitating timely and personalized treatment interventions. Additionally, the integration of artificial intelligence and machine learning in healthcare systems is revolutionizing AHF therapy by improving the accuracy of patient assessments and optimizing treatment protocols. The development of novel pharmaceuticals and expansion of treatment modalities, such as gene therapy and biologics, are broadening the spectrum of therapeutic options available, appealing to a diverse patient population and healthcare providers. Moreover, changes in the regulatory and reimbursement landscape are encouraging the adoption of advanced, albeit often expensive, treatments. As AHF continues to be a major cause of hospital readmission and mortality, these factors collectively contribute to the dynamic advancement and adoption of new therapeutic strategies, shaping the future of AHF management.

Select Competitors (Total 93 Featured) -

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardiorentis AG
  • CVie Therapeutics Limited
  • Cytokinetics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • PhaseBio Pharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Acute Heart Failure (AHF) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Diagnostic Tools Propel Growth
    • Novel Drug Development Expands Addressable Market Opportunity
    • Personalized Medicine Strengthens Business Case for Targeted Therapies
    • Aging Population and Increasing Incidence Rates Drive Demand
    • Technological Innovations in Drug Delivery Systems Accelerate Market Growth
    • Regulatory Approvals for New Therapies Spur Market Expansion
    • Increased Healthcare Expenditure Sustains Growth
    • Rising Awareness and Early Diagnosis Generate Demand
    • Integration of AI and Big Data in Clinical Trials Throws the Spotlight on Precision Medicine
    • Increasing Use of Biomarkers in AHF Diagnosis and Treatment Generates Demand
    • Telemedicine and Remote Monitoring Solutions Propel Market Growth
    • Evolution of Value-Based Care Models Spurs Demand for Effective AHF Therapies
    • Expansion of Biopharmaceutical Industry Boosts Innovation in AHF Therapeutics
    • Advances in Genetic Research and Genomics Strengthen Personalized Treatment Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acute Heart Failure (AHF) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cardiac Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Cardiac Glycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for B-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for B-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Home Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: USA 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: USA 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Canada 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • JAPAN
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Japan 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • CHINA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 34: China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: China 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 36: China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: China 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • EUROPE
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 42: Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • FRANCE
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: France 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 46: France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: France 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • GERMANY
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Germany 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 50: Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Germany 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • ITALY
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Italy 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 54: Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Italy 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • UNITED KINGDOM
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 56: UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: UK 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 58: UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: UK 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • SPAIN
    • TABLE 60: Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Spain 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 62: Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Spain 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • RUSSIA
    • TABLE 64: Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Russia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 66: Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Russia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 68: Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 70: Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Rest of Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 72: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 73: Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2024 & 2030
    • TABLE 74: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 76: Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • AUSTRALIA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 78: Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: Australia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 80: Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Australia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • INDIA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 82: India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: India 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 84: India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: India 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • SOUTH KOREA
    • TABLE 86: South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: South Korea 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 88: South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: South Korea 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 90: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Rest of Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 92: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • LATIN AMERICA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 94: Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 95: Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2024 & 2030
    • TABLE 96: Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 98: Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • ARGENTINA
    • TABLE 100: Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 101: Argentina 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 102: Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 103: Argentina 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • BRAZIL
    • TABLE 104: Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Brazil 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 106: Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 107: Brazil 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • MEXICO
    • TABLE 108: Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 109: Mexico 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 110: Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Mexico 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 112: Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 113: Rest of Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 114: Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 115: Rest of Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • MIDDLE EAST
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 116: Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 117: Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2024 & 2030
    • TABLE 118: Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 119: Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 120: Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 121: Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • IRAN
    • TABLE 122: Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Iran 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 124: Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 125: Iran 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • ISRAEL
    • TABLE 126: Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 127: Israel 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 128: Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Israel 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • SAUDI ARABIA
    • TABLE 130: Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 131: Saudi Arabia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 132: Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 133: Saudi Arabia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 134: UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: UAE 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 136: UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 137: UAE 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 138: Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 139: Rest of Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 140: Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030
  • AFRICA
    • Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 142: Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 143: Africa 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2024 & 2030
    • TABLE 144: Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 145: Africa 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION